首页 | 本学科首页   官方微博 | 高级检索  
     


Therapeutic Potential of Highly Selective A3 Adenosine Receptor Ligands in the Central and Peripheral Nervous System
Authors:Elisabetta Coppi  Federica Cherchi  Martina Venturini  Elena Lucarini  Renato Corradetti  Lorenzo Di Cesare Mannelli  Carla Ghelardini  Felicita Pedata  Anna Maria Pugliese
Affiliation:Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy; (M.V.); (E.L.); (R.C.); (L.D.C.M.); (C.G.); (F.P.)
Abstract:Ligands of the Gi protein-coupled adenosine A3 receptor (A3R) are receiving increasing interest as attractive therapeutic tools for the treatment of a number of pathological conditions of the central and peripheral nervous systems (CNS and PNS, respectively). Their safe pharmacological profiles emerging from clinical trials on different pathologies (e.g., rheumatoid arthritis, psoriasis and fatty liver diseases) confer a realistic translational potential to these compounds, thus encouraging the investigation of highly selective agonists and antagonists of A3R. The present review summarizes information on the effect of latest-generation A3R ligands, not yet available in commerce, obtained by using different in vitro and in vivo models of various PNS- or CNS-related disorders. This review places particular focus on brain ischemia insults and colitis, where the prototypical A3R agonist, Cl-IB-MECA, and antagonist, MRS1523, have been used in research studies as reference compounds to explore the effects of latest-generation ligands on this receptor. The advantages and weaknesses of these compounds in terms of therapeutic potential are discussed.
Keywords:adenosine receptors   oxygen and glucose deprivation   anoxic depolarization   neurotransmission   hippocampus   dorsal root ganglion neurons   visceral pain   N-type calcium channels   A3 receptor agonists   A3 receptor antagonists
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号